1932

Abstract

Eosinophilic esophagitis (EoE) is a relatively recently identified but now frequently encountered antigen/immune-mediated disease which places significant burden on patients and the healthcare system. With its growing prevalence and recognition by healthcare providers in multiple disciplines, substantial progress has been made regarding the diagnostic criteria, clinical evaluation, tools for disease assessment, and immune pathways related to pathogenesis. Current treatment goals focus on the amelioration of inflammation and prevention of remodeling consequences using proton pump inhibitors, swallowed topical steroids, elimination diets, and esophageal dilation. Ongoing research holds promise for more efficacious and targeted therapies as well as a personalized approach to the care of patients with EoE.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-052819-023848
2021-01-27
2024-06-23
Loading full text...

Full text loading...

/deliver/fulltext/med/72/1/annurev-med-052819-023848.html?itemId=/content/journals/10.1146/annurev-med-052819-023848&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Dellon ES, Hirano I. 2018. Epidemiology and natural history of eosinophilic esophagitis. Gastroenterology 154:319–32 e3
    [Google Scholar]
  2. 2. 
    Jensen ET, Kappelman MD, Martin CF, Dellon ES 2015. Health-care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States. Am. J. Gastroenterol. 110:626–32
    [Google Scholar]
  3. 3. 
    Attwood SE, Smyrk TC, Demeester TR, Jones JB 1993. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig. Dis. Sci. 38:109–16
    [Google Scholar]
  4. 4. 
    Straumann A, Spichtin HP, Bernoulli R et al. 1994. Idiopathische, eosinophile Osophagitis: eine häufig verkannte Krankheit mit typischer Klinik und diskretem endoskopischem Bild. [Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings]. Schweiz. Med. Wochenschr. 124:1419–29
    [Google Scholar]
  5. 5. 
    Kelly KJ, Lazenby AJ, Rowe PC et al. 1995. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology 109:1503–12
    [Google Scholar]
  6. 6. 
    Dellon ES, Erichsen R, Baron JA et al. 2015. The increasing incidence and prevalence of eosinophilic oesophagitis outpaces changes in endoscopic and biopsy practice: national population-based estimates from Denmark. Aliment Pharmacol. Ther. 41:662–70
    [Google Scholar]
  7. 7. 
    Syed AA, Andrews CN, Shaffer E et al. 2012. The rising incidence of eosinophilic oesophagitis is associated with increasing biopsy rates: a population-based study. Aliment Pharmacol. Ther. 36:950–58
    [Google Scholar]
  8. 8. 
    van Rhijn BD, Verheij J, Smout AJ, Bredenoord AJ 2013. Rapidly increasing incidence of eosinophilic esophagitis in a large cohort. Neurogastroenterol. Motil. 25:47–52
    [Google Scholar]
  9. 9. 
    Arias A, Perez-Martinez I, Tenias JM, Lucendo AJ 2016. Systematic review with meta-analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment Pharmacol. Ther. 43:3–15
    [Google Scholar]
  10. 10. 
    Limketkai BN, Shah SC, Hirano I et al. 2019. Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis. Gut 68:2152–60
    [Google Scholar]
  11. 11. 
    Dellon ES, Liacouras CA, Molina-Infante J et al. 2018. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE Conference. Gastroenterology 155:1022–33
    [Google Scholar]
  12. 12. 
    Furuta GT, Liacouras CA, Collins MH et al. 2007. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 133:1342–63
    [Google Scholar]
  13. 13. 
    Rank MA, Sharaf RN, Furuta GT et al. 2020. Technical review on the management of eosinophilic esophagitis: a report from the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters. Gastroenterology 158:1789–810
    [Google Scholar]
  14. 14. 
    Liacouras CA, Furuta GT, Hirano I et al. 2011. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J. Allergy Clin. Immunol. 128:3–20
    [Google Scholar]
  15. 15. 
    Cheng E, Zhang X, Huo X et al. 2013. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut 62:824–32
    [Google Scholar]
  16. 16. 
    Mukkada VA, Haas A, Maune NC et al. 2010. Feeding dysfunction in children with eosinophilic gastrointestinal diseases. Pediatrics 126:e672–77
    [Google Scholar]
  17. 17. 
    Aceves SS, Newbury RO, Dohil MA et al. 2009. A symptom scoring tool for identifying pediatric patients with eosinophilic esophagitis and correlating symptoms with inflammation. Ann. Allergy Asthma Immunol. 103:401–6
    [Google Scholar]
  18. 18. 
    Mackenzie SH, Go M, Chadwick B et al. 2008. Eosinophilic oesophagitis in patients presenting with dysphagia—a prospective analysis. Aliment Pharmacol. Ther. 28:1140–46
    [Google Scholar]
  19. 19. 
    Desai TK, Stecevic V, Chang CH et al. 2005. Association of eosinophilic inflammation with esophageal food impaction in adults. Gastrointest. Endosc. 61:795–801
    [Google Scholar]
  20. 20. 
    Kidambi T, Toto E, Ho N et al. 2012. Temporal trends in the relative prevalence of dysphagia etiologies from 1999–2009. World J. Gastroenterol. 18:4335–41
    [Google Scholar]
  21. 21. 
    Hirano I, Moy N, Heckman MG et al. 2013. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut 62:489–95
    [Google Scholar]
  22. 22. 
    Aceves SS, Newbury RO, Dohil R et al. 2007. Esophageal remodeling in pediatric eosinophilic esophagitis. J. Allergy Clin. Immunol. 119:206–12
    [Google Scholar]
  23. 23. 
    Collins MH, Martin LJ, Alexander ES et al. 2017. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis. Esophagus 30:1–8
    [Google Scholar]
  24. 24. 
    Alexander JA. 2018. Endoscopic and radiologic findings in eosinophilic esophagitis. Gastrointest. Endosc. Clin. N. Am. 28:47–57
    [Google Scholar]
  25. 25. 
    Gentile N, Katzka D, Ravi K et al. 2014. Oesophageal narrowing is common and frequently under-appreciated at endoscopy in patients with oesophageal eosinophilia. Aliment Pharmacol. Ther. 40:1333–40
    [Google Scholar]
  26. 26. 
    Peery AF, Dellon ES, Lund J et al. 2012. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 143:1179–87
    [Google Scholar]
  27. 27. 
    Kia L, Hirano I. 2015. Distinguishing GERD from eosinophilic oesophagitis: concepts and controversies. Nat. Rev. Gastroenterol. Hepatol. 12:379–86
    [Google Scholar]
  28. 28. 
    Kwiatek MA, Hirano I, Kahrilas PJ et al. 2011. Mechanical properties of the esophagus in eosinophilic esophagitis. Gastroenterology 140:82–90
    [Google Scholar]
  29. 29. 
    Nicodeme F, Hirano I, Chen J et al. 2013. Esophageal distensibility as a measure of disease severity in patients with eosinophilic esophagitis. Clin. Gastroenterol. Hepatol. 11:1101–7
    [Google Scholar]
  30. 30. 
    Schoepfer A, Safroneeva E, Straumann A 2016. How to measure disease activity in eosinophilic esophagitis. Dis. Esophagus 29:959–66
    [Google Scholar]
  31. 31. 
    Furuta GT, Kagalwalla AF, Lee JJ et al. 2013. The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis. Gut 62:1395–405
    [Google Scholar]
  32. 32. 
    Katzka DA, Geno DM, Ravi A et al. 2015. Accuracy, safety, and tolerability of tissue collection by Cytosponge vs endoscopy for evaluation of eosinophilic esophagitis. Clin. Gastroenterol. Hepatol. 13:77–83
    [Google Scholar]
  33. 33. 
    Blanchard C, Rothenberg ME. 2008. Basic pathogenesis of eosinophilic esophagitis. Gastrointest. Endosc. Clin. N. Am. 18:133–43
    [Google Scholar]
  34. 34. 
    Mishra A, Hogan SP, Lee JJ et al. 1999. Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J. Clin. Investig. 103:1719–27
    [Google Scholar]
  35. 35. 
    Davis BP, Stucke EM, Khorki ME et al. 2016. Eosinophilic esophagitis-linked calpain 14 is an IL-13-induced protease that mediates esophageal epithelial barrier impairment. JCI Insight 1:e86355
    [Google Scholar]
  36. 36. 
    Sherrill JD, Kc K, Wu D et al. 2014. Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis. Mucosal Immunol 7:718–29
    [Google Scholar]
  37. 37. 
    Abonia JP, Blanchard C, Butz BB et al. 2010. Involvement of mast cells in eosinophilic esophagitis. J. Allergy Clin. Immunol. 126:140–49
    [Google Scholar]
  38. 38. 
    Dellon ES, Gonsalves N, Hirano I et al. 2013. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am. J. Gastroenterol. 108:679–92
    [Google Scholar]
  39. 39. 
    Straumann A, Spichtin HP, Grize L et al. 2003. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 125:1660–69
    [Google Scholar]
  40. 40. 
    Schoepfer AM, Safroneeva E, Bussmann C et al. 2013. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology 145:1230–36
    [Google Scholar]
  41. 41. 
    Stern E, Taft T, Zalewski A et al. 2018. Prospective assessment of disease-specific quality of life in adults with eosinophilic esophagitis. Dis. Esophagus 31:dox128
    [Google Scholar]
  42. 42. 
    Hirano I, Aceves SS. 2014. Clinical implications and pathogenesis of esophageal remodeling in eosinophilic esophagitis. Gastroenterol. Clin. N. Am. 43:297–316
    [Google Scholar]
  43. 43. 
    Hirano I, Chan ES, Rank MA et al. 2020. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology 158:1776–86
    [Google Scholar]
  44. 44. 
    Hirano I, Furuta GT. 2020. Approaches and challenges to management of pediatric and adult patients with eosinophilic esophagitis. Gastroenterology 158:840–51
    [Google Scholar]
  45. 45. 
    Lucendo AJ, Molina-Infante J, Arias A et al. 2017. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United Eur. Gastroenterol. J. 5:335–58
    [Google Scholar]
  46. 46. 
    Kagalwalla AF, Sentongo TA, Ritz S et al. 2006. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin. Gastroenterol. Hepatol. 4:1097–102
    [Google Scholar]
  47. 47. 
    Gonsalves N, Yang GY, Doerfler B et al. 2012. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology 142:1451–59
    [Google Scholar]
  48. 48. 
    Lucendo AJ, Arias A, Gonzalez-Cervera J et al. 2013. Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: a prospective study on the food cause of the disease. J. Allergy Clin. Immunol. 131:797–804
    [Google Scholar]
  49. 49. 
    Warners MJ, Vlieg-Boerstra BJ, Verheij J et al. 2017. Elemental diet decreases inflammation and improves symptoms in adult eosinophilic oesophagitis patients. Aliment Pharmacol. Ther. 45:777–87
    [Google Scholar]
  50. 50. 
    Arias A, Gonzalez-Cervera J, Tenias JM, Lucendo AJ 2014. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology 146:1639–48
    [Google Scholar]
  51. 51. 
    Simon D, Straumann A, Wenk A et al. 2006. Eosinophilic esophagitis in adults—no clinical relevance of wheat and rye sensitizations. Allergy 61:1480–83
    [Google Scholar]
  52. 52. 
    Molina-Infante J, Martin-Noguerol E, Alvarado-Arenas M et al. 2012. Selective elimination diet based on skin testing has suboptimal efficacy for adult eosinophilic esophagitis. J. Allergy Clin. Immunol. 130:1200–2
    [Google Scholar]
  53. 53. 
    Eckmann JD, Ravi K, Katzka DA et al. 2018. Efficacy of atopy patch testing in directed dietary therapy of eosinophilic esophagitis: a pilot study. Dig. Dis. Sci. 63:694–702
    [Google Scholar]
  54. 54. 
    Molina-Infante J, Arias A, Barrio J et al. 2014. Four-food group elimination diet for adult eosinophilic esophagitis: a prospective multicenter study. J. Allergy Clin. Immunol. 134:1093–99
    [Google Scholar]
  55. 55. 
    Doerfler B, Bryce P, Hirano I, Gonsalves N 2015. Practical approach to implementing dietary therapy in adults with eosinophilic esophagitis: the Chicago experience. Dis. Esophagus 28:42–58
    [Google Scholar]
  56. 56. 
    Kagalwalla AF, Wechsler JB, Amsden K et al. 2017. Efficacy of a 4-food elimination diet for children with eosinophilic esophagitis. Clin. Gastroenterol. Hepatol. 15:1698–707
    [Google Scholar]
  57. 57. 
    Kagalwalla AF, Amsden K, Shah A et al. 2012. Cow's milk elimination: a novel dietary approach to treat eosinophilic esophagitis. J. Pediatr. Gastroenterol. Nutr. 55:711–16
    [Google Scholar]
  58. 58. 
    Molina-Infante J, Arias A, Alcedo J et al. 2018. Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: the 2-4-6 study. J. Allergy Clin. Immunol. 141:1365–72
    [Google Scholar]
  59. 59. 
    Wolf WA, Huang KZ, Durban R et al. 2016. The six-food elimination diet for eosinophilic esophagitis increases grocery shopping cost and complexity. Dysphagia 31:765–70
    [Google Scholar]
  60. 60. 
    Gonsalves N, Kagalwalla AF. 2014. Dietary treatment of eosinophilic esophagitis. Gastroenterol. Clin. N. Am. 43:375–83
    [Google Scholar]
  61. 61. 
    Lieberman JA, Zhang J, Whitworth J, Cavender C 2018. A randomized, double-blinded, placebo-controlled study of the use of viscous oral cromolyn sodium for the treatment of eosinophilic esophagitis. Ann. Allergy Asthma Immunol. 120:527–31
    [Google Scholar]
  62. 62. 
    Assa'ad AH, Gupta SK, Collins MH et al. 2011. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 141:1593–604
    [Google Scholar]
  63. 63. 
    Stein ML, Collins MH, Villanueva JM et al. 2006. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J. Allergy Clin. Immunol. 118:1312–19
    [Google Scholar]
  64. 64. 
    Straumann A, Conus S, Grzonka P et al. 2010. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 59:21–30
    [Google Scholar]
  65. 65. 
    Spergel JM, Rothenberg ME, Collins MH et al. 2012. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 129:456–63
    [Google Scholar]
  66. 66. 
    Rothenberg ME, Wen T, Greenberg A et al. 2015. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J. Allergy Clin. Immunol. 135:500–7
    [Google Scholar]
  67. 67. 
    Hirano I, Collins MH, Assouline-Dayan Y et al. 2019. RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis. Gastroenterology 156:592–603
    [Google Scholar]
  68. 68. 
    Hirano I, Dellon ES, Hamilton JD et al. 2020. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology 158:111–22
    [Google Scholar]
  69. 69. 
    Clayton F, Fang JC, Gleich GJ et al. 2014. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. Gastroenterology 147:602–9
    [Google Scholar]
  70. 70. 
    Straumann A, Hoesli S, Bussmann C et al. 2013. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy 68:375–85
    [Google Scholar]
  71. 71. 
    Hirano I, Peterson K, Murray J et al. 2020. AK002, an anti-SIGLEC-8 antibody, depletes tissue eosinophils and improves dysphagia symptoms in patients with eosinophilic esophagitis. J. Allergy Clin. Immunol. 145:AB167
    [Google Scholar]
  72. 72. 
    Straumann A, Bussmann C, Conus S et al. 2008. Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis. J. Allergy Clin. Immunol. 122:425–27
    [Google Scholar]
  73. 73. 
    Netzer P, Gschossmann JM, Straumann A et al. 2007. Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission. Eur. J. Gastroenterol. Hepatol. 19:865–69
    [Google Scholar]
  74. 74. 
    Hirano I 2018. How to approach a patient with eosinophilic esophagitis. Gastroenterology 155:601–6
    [Google Scholar]
/content/journals/10.1146/annurev-med-052819-023848
Loading
/content/journals/10.1146/annurev-med-052819-023848
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error